Our global life sciences company brings diagnostic testing & drug development together. Explore what we do.
Pharmaceutical companies are using our HCV resistance assays to support all phases of research and clinical development for several new HCV compounds. Our phenotypic and genotypic sequencing assays offered to pharmaceutical companies target all the major steps in the HCV replication cycle, including the NS3 protease, NS5A, and the NS5B polymerase. As more compounds reach the clinic, our assays will continue to provide useful information for the incorporation of DAAs into patient management.
For more information about Monogram’s full line of HIV, HCV, or pharmaceutical services, visit our Pharma Collaborations page.